Lilly will also present final, long-term results at FCD from the BRAVE-AA1/BRAVE-AA2 studies. Among adults with severe AA who responded to baricitinib at 52 weeks, 86.5% of patients receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results